X Mariette

Summary

Country: France

Publications

  1. ncbi request reprint [Pathophysiological advances underlying the biotherapeutic revolution in inflammatory rheumatism]
    Xavier Mariette
    Rhumatologie, Hôpitaux Universitaires Paris Sud, AP HP, Universite Paris Sud, INSERM U1012, Le Kremlin Bicetre
    Bull Acad Natl Med 196:1261-76; discussion 1276-8. 2012
  2. doi request reprint Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy
    Xavier Mariette
    Rhumatologie, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Universite Paris Sud 11, INSERM U1012, 78 rue du General Leclerc, Le Kremlin Bicetre, France
    Ann Rheum Dis 71:1783-90. 2012
  3. pmc How does BAFF activate B cells in patients with autoimmune diseases?
    Xavier Mariette
    Service de Rhumatologie, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Universite Paris Sud, Institut Pour la Santé et la Recherche Médicale INSERM U 1012, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Arthritis Res Ther 14:106. 2012
  4. pmc Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies
    Corinne Miceli-Richard
    Rhumatologie, Hopital Bicetre, Assistance Publique Hopitaux de Paris, 94275 Le Kremlin Bicetre, France
    Arthritis Res Ther 11:R77. 2009
  5. pmc CTLA-4 +49A/G and CT60 gene polymorphisms in primary Sjögren syndrome
    Jacques Eric Gottenberg
    Rhumatologie, Institut Pour la Santé et la Recherche Médicale U802, Universite Paris Sud 11, Hopital Bicetre, 78 rue du General Leclerc, Assistance Publique Hopitaux de Paris, 94275 Le Kremlin Bicetre, France
    Arthritis Res Ther 9:R24. 2007
  6. pmc Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity
    Jeremie Sellam
    Rhumatologie, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, INSERM U802, Universite Paris Sud 11, 78 rue du General Leclerc, 94270, Le Kremlin Bicetre, France
    Arthritis Res Ther 11:R156. 2009
  7. pmc Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
    Jacques Tebib
    Service de Rhumatologie, Centre Hospitalier Lyon Sud, 765 chemin du Grand Revoyet, 69495 Pierre Benite, France
    Arthritis Res Ther 11:R95. 2009
  8. pmc Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
    Melanie Gilson
    Rheumatology B Department, Cochin Hospital, Paris 75014, France
    Arthritis Res Ther 12:R145. 2010
  9. doi request reprint Pathogenesis of Sjögren's syndrome and therapeutic consequences
    Xavier Mariette
    Hopital Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Institut Pour la Santé et la Recherche Médicale U1012, Le Kremlin Bicetre, France
    Curr Opin Rheumatol 22:471-7. 2010
  10. ncbi request reprint Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
    Xavier Mariette
    Hopital Bicetre, Institut Pour la Santé et Recherche Médicale INSERM U 1012, Universite Paris Sud 11, Le Kremlin Bicetre, France
    Ann Rheum Dis 70:1895-904. 2011

Collaborators

Detail Information

Publications77

  1. ncbi request reprint [Pathophysiological advances underlying the biotherapeutic revolution in inflammatory rheumatism]
    Xavier Mariette
    Rhumatologie, Hôpitaux Universitaires Paris Sud, AP HP, Universite Paris Sud, INSERM U1012, Le Kremlin Bicetre
    Bull Acad Natl Med 196:1261-76; discussion 1276-8. 2012
    ..TNF inhibitors are effective in spondyloarthritis. In lupusandSjigren'ssyndrome, genes stimulatedby IFNtypel are hyper-expressed, along with BAFF (or BLyS), a B lymphocyte-activating cytokine...
  2. doi request reprint Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy
    Xavier Mariette
    Rhumatologie, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Universite Paris Sud 11, INSERM U1012, 78 rue du General Leclerc, Le Kremlin Bicetre, France
    Ann Rheum Dis 71:1783-90. 2012
    ....
  3. pmc How does BAFF activate B cells in patients with autoimmune diseases?
    Xavier Mariette
    Service de Rhumatologie, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Universite Paris Sud, Institut Pour la Santé et la Recherche Médicale INSERM U 1012, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Arthritis Res Ther 14:106. 2012
    ..The origin and pathways involved in this higher susceptibility to BAFF-driven IL-6 induction by monocytes of patients with SS are still unknown...
  4. pmc Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies
    Corinne Miceli-Richard
    Rhumatologie, Hopital Bicetre, Assistance Publique Hopitaux de Paris, 94275 Le Kremlin Bicetre, France
    Arthritis Res Ther 11:R77. 2009
    ..We investigated the EBV load and EBV-specific T-cell response in patients treated with methotrexate (MTX) or anti-TNF therapy...
  5. pmc CTLA-4 +49A/G and CT60 gene polymorphisms in primary Sjögren syndrome
    Jacques Eric Gottenberg
    Rhumatologie, Institut Pour la Santé et la Recherche Médicale U802, Universite Paris Sud 11, Hopital Bicetre, 78 rue du General Leclerc, Assistance Publique Hopitaux de Paris, 94275 Le Kremlin Bicetre, France
    Arthritis Res Ther 9:R24. 2007
    ..In fact, sampling bias may account for some contradictory results previously reported for CTLA-4 association studies in autoimmune diseases...
  6. pmc Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity
    Jeremie Sellam
    Rhumatologie, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, INSERM U802, Universite Paris Sud 11, 78 rue du General Leclerc, 94270, Le Kremlin Bicetre, France
    Arthritis Res Ther 11:R156. 2009
    ....
  7. pmc Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
    Jacques Tebib
    Service de Rhumatologie, Centre Hospitalier Lyon Sud, 765 chemin du Grand Revoyet, 69495 Pierre Benite, France
    Arthritis Res Ther 11:R95. 2009
    ..This study evaluates the safety and efficacy of masitinib (AB1010), a potent and selective protein tyrosine kinase inhibitor of c-KIT, in the monotherapy treatment of DMARD-refractory RA...
  8. pmc Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
    Melanie Gilson
    Rheumatology B Department, Cochin Hospital, Paris 75014, France
    Arthritis Res Ther 12:R145. 2010
    ....
  9. doi request reprint Pathogenesis of Sjögren's syndrome and therapeutic consequences
    Xavier Mariette
    Hopital Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Institut Pour la Santé et la Recherche Médicale U1012, Le Kremlin Bicetre, France
    Curr Opin Rheumatol 22:471-7. 2010
    ....
  10. ncbi request reprint Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
    Xavier Mariette
    Hopital Bicetre, Institut Pour la Santé et Recherche Médicale INSERM U 1012, Universite Paris Sud 11, Le Kremlin Bicetre, France
    Ann Rheum Dis 70:1895-904. 2011
    ..This project was undertaken to assess the risk of malignancy in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors (TNFi) in clinical practice, as recorded in prospective, observational studies...
  11. pmc Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry
    F Tubach
    Universite Paris 7 Denis Diderot, INSERM U738, Assistance Publique Hopitaux de Paris AP HP, Hopital Bichat, Biostatistique et Recherche Clinique, Paris, France
    Arthritis Rheum 60:1884-94. 2009
    ..Our objective was to describe cases of TB associated with anti-TNF mAb therapy, identify risk factors, and estimate the incidence...
  12. doi request reprint Is Inhibitor of differentiation 3 involved in human primary Sjögren's syndrome?
    J Sellam
    Rhumatologie, INSERM U802, Hopital Bicetre, Assistance Publique des Hopitaux de Paris, Universite Paris Sud, Le Kremlin Bicetre, France
    Rheumatology (Oxford) 47:437-41. 2008
    ..The impairment of Id3 in T cells and, possibly, in salivary glandular epithelial cells (SGECs) seems to be involved. This animal model prompted us to investigate the role of Id3 in human pSS...
  13. doi request reprint STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling
    N Gestermann
    Rhumatologie, Institut Pour la Santé et la Recherche Médicale INSERM U802, Universite Paris Sud 11, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Le Kremlin Bicetre, France
    Genes Immun 11:432-8. 2010
    ..51), MX1 (P=2 x 10(-4), r=0.63) and IFITM1 (P=8 x 10(-3), r=0.47), suggesting that STAT4 might be involved in not only type 2 IFN production but also in type 1 IFN-mediated effects...
  14. pmc Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome
    J E Gottenberg
    Service de Rhumatologie, Hopital de Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 64:1050-5. 2005
    ..In primary Sjögren's syndrome (pSS), extraglandular involvement might result from more intense stimulation of autoreactive B cells. Thus markers of B cell activation could be useful in the clinical assessment of this disease...
  15. pmc Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry
    X Mariette
    Hopital de Bicetre, Le Kremlin Bicetre, France
    Ann Rheum Dis 69:400-8. 2010
    ..To describe cases of lymphoma associated with anti-TNF therapy, identify risk factors, estimate the incidence and compare the risks for different anti-TNF agents...
  16. doi request reprint Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry
    J E Gottenberg
    Rhumatologie, Hopitaux Universitaires de Strasbourg, Centre de Référence National des Maladies Auto Immunes Systémique Rares, EA 4438 Physiopathologie des Arthrites, Strasbourg, France
    Ann Rheum Dis 71:1815-9. 2012
    ..Very limited data are available regarding the efficacy of abatacept (ABA) in real life. The aims of this study were to determine the efficacy of ABA in rheumatoid arthritis and predicting factors of efficacy in common practice...
  17. pmc Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome
    J E Gottenberg
    Rhumatologie, Universite Paris Sud 11, INSERM U802, Hopital Bicetre, Assistance Publique des Hopitaux de Paris, Le Kremlin Bicetre, France
    Ann Rheum Dis 66:23-7. 2007
    ..B cell activation may result in an increased secretion of immunoglobulin free light chains (FLCs) in autoimmune diseases...
  18. pmc A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis
    C Miceli-Richard
    Rhumatologie, Institut Pour la Santé et la Recherche Médicale U 802, Universite Paris Sud 11, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    Ann Rheum Dis 67:478-84. 2008
    ..To determine whether tumour necrosis factor (TNF) gene polymorphisms and/or the shared epitope are genetic predictors of the response to adalimumab (ADA) in rheumatoid arthritis (RA)...
  19. doi request reprint Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry
    A Mekinian
    Department of Internal Medicine, Hopital Jean Verdier, Assistance Publique Hopitaux de Paris, Université Paris Sud 13, Bondy, France
    Ann Rheum Dis 71:84-7. 2012
    ..To evaluate rituximab (RTX) in primary Sjögren's syndrome (pSS) with peripheral nervous system (PNS) involvement...
  20. ncbi request reprint Upregulation of membrane-bound CD40L on CD4+ T cells in women with primary Sjögren's syndrome
    R Belkhir
    Institut National de la Santé et de la Recherche Médicale INSERM U1012, Le Kremlin Bicetre, France Université Paris Sud, Hôpitaux Universitaires Paris Sud, AP HP, Le Kremlin Bicetre, France
    Scand J Immunol 79:37-42. 2014
    ..Inducible membrane-bound CD40L on CD4(+) T cells is increased in patients with pSS but was not related to epigenetic deregulation by demethylation patterns of the regulatory regions of CD40L...
  21. doi request reprint Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry
    B Terrier
    Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie Paris 6, Paris, France
    Arthritis Care Res (Hoboken) 62:1787-95. 2010
    ..Rituximab has emerged as a novel and promising therapeutic alternative, but data are scarce. Our objective was to evaluate the safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis in off-trial real-life patients...
  22. doi request reprint B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome
    F Lavie
    Rheumatology Department, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Institut Pour Santé et Recherche Médicale INSERM U802, Universite Paris Sud 11, Le Kremlin Bicetre, France
    Scand J Immunol 67:185-92. 2008
    ..BAFF expression is also increased in blood T cells of such patients, independently of T-cell stimulation...
  23. pmc Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
    J E Gottenberg
    Service de Rhumatologie, Hopital de Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 64:913-20. 2005
    ..To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice...
  24. doi request reprint Azathioprine or methotrexate maintenance for ANCA-associated vasculitis
    Christian Pagnoux
    Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    N Engl J Med 359:2790-803. 2008
    ..However, azathioprine and methotrexate have not been compared with regard to safety and efficacy...
  25. doi request reprint Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database
    Christian Pagnoux
    Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Arthritis Rheum 62:616-26. 2010
    ..This study was undertaken to describe the main characteristics of and long-term outcomes in patients with well-characterized PAN diagnoses...
  26. doi request reprint Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
    D Salmon-Ceron
    Service de Rhumatologie, Hopital Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre
    Ann Rheum Dis 70:616-23. 2011
    ..Anti-tumour necrosis factor (TNF) therapy may be associated with opportunistic infections (OIs)...
  27. ncbi request reprint Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists
    F Tubach
    Universite Paris 7, Faculte de Medecine, Paris, France
    Clin Infect Dis 43:e95-100. 2006
    ..Patients treated with tumor necrosis factor-alpha (TNF-alpha) antagonists have an increased risk of infection, but infection due to Legionella pneumophila has rarely been described in patients receiving such therapy...
  28. ncbi request reprint Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis
    Bruno Fautrel
    Pierre and Marie Curie University Paris VI, UFR de Medecine, France
    Joint Bone Spine 74:627-37. 2007
    ..To update French Society for Rheumatology guidelines regarding the use of TNFalpha antagonists for treating patients with rheumatoid arthritis (RA)...
  29. ncbi request reprint B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study
    Jeremie Sellam
    Hopital Bicetre, Assistance Publique Hopitaux de Paris, INSERM U1012, and Université Paris Sud 11, Le Kremlin Bicetre, France
    Arthritis Rheum 63:933-8. 2011
    ..To examine whether serum B cell markers can predict response to rituximab, a B cell-depleting monoclonal antibody, in patients with refractory rheumatoid arthritis (RA)...
  30. doi request reprint B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study
    Jeremie Sellam
    Hopital Bicetre, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    Arthritis Rheum 63:933-8. 2011
    ..To examine whether serum B cell markers can predict response to rituximab, a B cell-depleting monoclonal antibody, in patients with refractory rheumatoid arthritis (RA)...
  31. ncbi request reprint The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy
    Florence Tubach
    INSERM U738, Bichat Teaching Hospital, Xavier Bichat School of Medicine, Paris 7 University, Paris, France
    Joint Bone Spine 72:456-60. 2005
    ....
  32. ncbi request reprint EBV-specific T-cell response and immunosuppression by methotrexate and TNFalpha antagonists in patients with chronic inflammatory joint disease
    Corinne Miceli-Richard
    Service de Rhumatologie, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Le Kremlin Bicetre, France
    Joint Bone Spine 74:560-2. 2007
  33. ncbi request reprint Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France
    Xavier Mariette
    Service de Rhumatologie, Hôpital de Bicêtre Assistance publique Hôpitaux de Paris AP HP, Le Kremlin Bicetre, France
    Blood 99:3909-15. 2002
    ..Thus, this 3-year prospective study indicated that, whereas the risk of NHL was not significantly increased in RA patients treated with MTX, the incidence of HD appeared to be higher in these patients compared to the French population...
  34. ncbi request reprint Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis
    Bruno Fautrel
    Service de Rhumatologie, Groupe Hospitalier Pitie Salpetriere, UFR de Medecine, Universite Pierre et Marie Curie Paris VI, 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Joint Bone Spine 73:433-41. 2006
    ..To develop recommendations for TNFalpha-antagonist therapy in patients with rheumatoid arthritis (RA) seen in everyday practice, under the aegis of the French Society for Rheumatology...
  35. doi request reprint Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment
    Maxime Breban
    Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Boulogne Billancourt, France
    Arthritis Rheum 58:88-97. 2008
    ..This study was undertaken to compare the efficacy of continuous treatment with infliximab with that of a treatment regimen adapted to symptom recurrence. Methotrexate (MTX) in combination with infliximab was also tested...
  36. pmc Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome
    J E Gottenberg
    Department of Rheumatology, Bicetre Hospital, INSERM EMI 109, Le Kremlin Bicetre, France
    Ann Rheum Dis 64:114-7. 2005
    ..To investigate the prevalence of anti-cyclic citrullinated peptide (anti-CCP) and anti-keratin antibodies (AKA) in patients with primary Sjögren's syndrome...
  37. ncbi request reprint [Treatment of oral dryness in Sjögren's syndrome]
    X Mariette
    Service de Rhumatologie, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Le Kremlin Bicetre, France
    Rev Med Interne 25:287-93. 2004
    ..In Sjögren's syndrome (SS), oral dryness is frequently the most bothersome symptom of sicca syndrome with negative affects on quality of life. A review of treatments of oral dryness is proposed...
  38. ncbi request reprint Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, Marseille, France
    Joint Bone Spine 73:379-87. 2006
    ..To develop clinical practice guidelines for the evaluation and management of cardiovascular risk in patients with rheumatoid arthritis (RA), using the evidence-based approach and expert opinion...
  39. ncbi request reprint TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, 147, Bd Baille, 13005 Marseille, France
    Joint Bone Spine 73:547-53. 2006
    ..To develop recommendations for TNFalpha antagonist therapy in patients with spondyloarthropathies...
  40. pmc Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
    Raphaele Seror
    Department of Rheumatology, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, INSERM U802, Le Kremlin Bicetre, France
    Ann Rheum Dis 66:351-7. 2007
    ..To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers...
  41. ncbi request reprint Hematological malignancies and the bone (myeloma excluded)
    S Roux
    Rheumatology Department, Bicêtre Teaching Hospital, Le Kremlin Bicetre, Paris, France
    Joint Bone Spine 67:264-71. 2000
    ..The unusual occurrence of bone lesions in these diseases probably implies distinct pathogenic mechanisms, but one can speculate that an increased expression of RANK/RANKL, the common final pathway in bone resorption, may be involved...
  42. doi request reprint European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients
    R Seror
    Universite Paris Sud, AP HP, Hôpitaux Universitaires Paris Sud, INSERM U1012, Le Kremlin Bicetre, France
    Arthritis Care Res (Hoboken) 65:1358-64. 2013
    ..We aimed to determine whether patients' symptoms differed between patients with and without systemic involvement and if the disease-specific indices correlated with each other in primary SS...
  43. ncbi request reprint No evidence for association between 1858 C/T single-nucleotide polymorphism of PTPN22 gene and primary Sjögren's syndrome
    M Ittah
    Service de Rhumatologie, Institut Pour la Santé et la Recherche Médicale E 109, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    Genes Immun 6:457-8. 2005
    ..PTPN 22 gene polymorphism was not associated with a specific pattern of autoantibody secretion either. Thus, 1858 C/T polymorphism of PTPN22 gene is not involved in genetic predisposition to pSS...
  44. pmc Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells
    X Mariette
    Department of Rheumatology, Hopital de Bicetre, Universite Paris Sud, Le Kremlin Bicetre, France
    Ann Rheum Dis 60:1007-10. 2001
    ....
  45. doi request reprint Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis
    Stephan Pavy
    Service de Rhumatologie, Hopital Bicetre, 78 Avenue du General LeClerc, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 69:1022-8. 2010
    ..Several studies have suggested that the rare A allele of the tumour necrosis factor alpha (TNFA) -308G-->A polymorphism could be associated with a poorer response to anti-TNF therapy. Nevertheless, these results remain controversial...
  46. doi request reprint Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry
    Benjamin Terrier
    Bicetre Hospital, Assistance Publique Hopitaux de Paris, and Paris 11 University, Le Kremlin Bicetre, France
    Arthritis Rheum 62:2458-66. 2010
    ..However, in 2 recent randomized controlled trials (RCTs) of RTX, the primary end points were not met. We undertook this study to evaluate the safety and efficacy of RTX in off-trial patients with SLE seen in regular clinical practice...
  47. ncbi request reprint Specific cardiomyopathy in lupus patients: report of three cases
    Jacques Eric Gottenberg
    Rheumatology Department, Hopital de Bicetre, Assistance Publique Hopitaux de Paris AP HP, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre cedex, France
    Joint Bone Spine 71:66-9. 2004
    ..It may be improved by steroids and immunosuppressive therapy. Literature concerning this cardiac manifestation in lupus is reviewed...
  48. doi request reprint Rituximab: a new therapeutic alternative in rheumatoid arthritis
    Jean Sibilia
    Service de Rhumatologie, CHU Strasbourg, Centre National de Référence des Maladies Auto immunes Systémiques Rares, Strasbourg, France
    Joint Bone Spine 75:526-32. 2008
    ..A longer follow-up duration and data from off-trial patients, included in registries, are now required...
  49. pmc Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production
    Frédéric Lavie
    Rheumatology Department, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Institut Pour la Santé et la Recherche Médicale INSERM U802, Universite Paris Sud 11, Le Kremlin Bicetre, France
    Ann Rheum Dis 66:700-3. 2007
    ..The cytokine B cell-activating factor of the TNF family (BAFF) is involved in the pathogenesis of autoimmune diseases...
  50. ncbi request reprint Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus
    Fanny Baran-Marszak
    INSERM E109, CHU Bicetre, Assistance Publique Hopitaux de Paris, Université Paris 11, 94275 Le Kremlin Bicetre, France
    Cytokine 33:337-45. 2006
    ..Thus, if an increased incidence of lymphoma were induced by TNFalpha blockers, it would not involve a direct effect on B cells but rather an impaired immune surveillance by T cells...
  51. ncbi request reprint Emerging biological therapies in rheumatoid arthritis
    Xavier Mariette
    Rheumatology Department, INSERM EMI 109, Bicêtre Teaching Hospital, Paris Sud University, Le Kremlin Bicetre, France
    Joint Bone Spine 71:470-4. 2004
    ..One of the challenges for the future is to identify ingenious combinations of biological therapies capable of improving the quality and duration of responses without exacerbating side effects...
  52. ncbi request reprint Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Frédéric Lavie
    Service de Rhumatologie, Hopital de Bicetre, Le Kremlin Bicetre, France
    Joint Bone Spine 74:346-52. 2007
    ..To develop recommendations about pharmacotherapy (excluding biotherapeutic agents) in patients with axial forms of ankylosing spondylitis (AS) seen in everyday clinical practice...
  53. ncbi request reprint Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Emmanuelle Dernis
    Service de Rhumatologie, CH Le Mans, Le Mans, France
    Joint Bone Spine 74:330-7. 2007
    ..To develop French recommendations about the clinical and laboratory follow-up of patients with axial ankylosing spondylitis (AS) seen in everyday practice...
  54. pmc French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers
    X Mariette
    Service de Rhumatologie, Hopital Bicetre, Le Kremlin Bicetre, Hopital Cochin, Paris, France Service de Médecine Interne, Hopital Cochin, Paris, France Recherche sur Anti TNF et Infections Opportunistes
    Ann Rheum Dis 62:791. 2003
  55. ncbi request reprint Evaluation of bone mineral density and fat-lean distribution in patients with multiple myeloma in sustained remission
    S Roux
    Department of Rheumatology, Bicetre Hospital, Le Kremlin Bicetre, France
    J Bone Miner Res 18:231-6. 2003
    ..Interestingly, a drastic increase of the fat content was also observed. These results underlined that BMD and fat-lean evaluation could be of interest in the follow-up of MM patients...
  56. pmc The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome
    X Mariette
    Service de Rhumatologie, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris XI, INSERM EMI 0109, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 62:168-71. 2003
    ..Increased levels of B lymphocyte stimulator (BLyS) have been detected in serum from patients with systemic lupus erythematosus and rheumatoid arthritis...
  57. ncbi request reprint Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion
    Bruno Fautrel
    Service de Rhumatologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Joint Bone Spine 72:163-70. 2005
    ..To develop recommendations for the information and education of patients with rheumatoid arthritis (RA) seen in everyday practice, using evidence from the literature, supplemented with expert opinion when needed...
  58. ncbi request reprint Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS)
    Xavier Mariette
    Service de Rhumatologie, Hôpital de Bicêtre AP HP, and Université Paris Sud, Le Kremlin Bicetre, France
    Arthritis Rheum 50:1270-6. 2004
    ..Since tumor necrosis factor alpha (TNF alpha) could be a key element in the pathogenesis of primary SS, we conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of infliximab in primary SS...
  59. pmc B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome
    Marc Ittah
    Rhumatologie, Institut Pour la Santé et la Recherche Médicale INSERM U 802, Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Universite Paris Sud 11, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Arthritis Res Ther 8:R51. 2006
    ..Our results suggest that an anti-BAFF therapeutic approach could be particularly interesting in pSS...
  60. doi request reprint Tocilizumab: therapy and safety management
    Thao Pham
    Service de Rhumatologie, CHU Conception, Marseille, France
    Joint Bone Spine 77:S3-100. 2010
    ..To develop fact sheets about tocilizumab, in order to assist physicians in the management of patients with inflammatory joint disease...
  61. pmc Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus
    Jeremie Sellam
    Service de Rhumatologie, Hopital de Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 66:790-7. 2007
    ..To analyse B cell activating factor (BAFF) receptor (BAFF-R) expression on peripheral lymphocytes from patients with primary Sjögren's syndrome (pSS) and systemic lupus erythematosus (SLE)...
  62. doi request reprint Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature
    Jean Marie Berthelot
    Service de Rhumatologie, Hotel Dieu, CHU Nantes, 44093, Nantes Cedex 01, France
    Joint Bone Spine 76:28-34. 2009
    ..To report on the outcome of 15 cases of pregnancies in women treated with anti-TNF drugs during conception or pregnancy..
  63. doi request reprint Abatacept therapy and safety management
    Thao Pham
    Service de Rhumatologie, CHU Conception, Marseille, France
    Joint Bone Spine 76:S3-S55. 2009
    ..To elaborate a how-to-use abatacept material intended to help physicians in the management of patients with inflammatory diseases treated with this drug in routine practice...
  64. ncbi request reprint Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome
    Frédéric Lavie
    Service de Rhumatologie, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
    J Pathol 202:496-502. 2004
    ..In conclusion, BAFF may be expressed by T cells at the site of autoimmune damage and could play a role in the pathogenesis of pSS, particularly by triggering the activation of self-antigen-driven autoimmune B cells...
  65. pmc Association of an IRF5 gene functional polymorphism with Sjögren's syndrome
    Corinne Miceli-Richard
    INSERM U802, Universite Paris Sud 11, Hopital Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Arthritis Rheum 56:3989-94. 2007
    ..The purpose of this case-control study was to investigate whether IRF5 polymorphisms are involved in the genetic predisposition to primary Sjögren's syndrome (SS), an autoimmune disease closely related to SLE...
  66. ncbi request reprint Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, Marseille, France
    Joint Bone Spine 72:222-8. 2005
    ..To develop recommendations for the physical and laboratory-test follow-up of patients with rheumatoid arthritis (RA) seen in everyday practice, using evidence from the literature, supplemented with expert opinion when needed...
  67. pmc No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome
    Jacques Eric Gottenberg
    Rhumatologie, INSERM E 109, Hopital Bicetre, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Le Kremlin Bicetre, France
    Arthritis Res Ther 8:R30. 2006
    ..01), although no correlation was observed between BAFF polymorphism and mRNA level. In conclusion, BAFF gene polymorphism is neither involved in genetic predisposition to pSS nor associated with a specific pattern of antibody production...
  68. pmc Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy
    Jeremie Sellam
    Service de Rhumatologie, Hopital de Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Ann Rheum Dis 66:1610-5. 2007
    ..We aimed to investigate in vitro blood assays with TB-specific antigens (CFP-10, ESAT-6), in immune-mediated inflammatory diseases (IMID) for LTBI screening...
  69. ncbi request reprint Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery
    Benjamin Terrier
    Department of Hematology, Hopital Necker Enfants Malades, Assistance Publique Hopitaux de Paris, université Paris V René Descartes, Paris, France
    Haematologica 92:e20-3. 2007
    ..Assessment of serum BAFF levels following rituximab could detect patients at risk of developing LON...
  70. ncbi request reprint Current and potential treatments for primary Sjögren's syndrome
    Xavier Mariette
    Rheumatology Department, Bicêtre Teaching Hospital, Le Kremlin Bicetre, Paris XI University, France
    Joint Bone Spine 69:363-6. 2002
    ....
  71. ncbi request reprint In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response
    Jacques Eric Gottenberg
    Service de Rhumatologie, Hopital de Bicetre, Assistance Publique Hopitaux de Paris AP HP, INSERM EMI 0109, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Arthritis Rheum 48:2240-5. 2003
    ..To reevaluate, in a large series of patients with Sjögren's syndrome (SS) recruited from 2 French centers, the question of whether HLA is associated with SS itself or with a pattern of secretion of autoantibodies...
  72. ncbi request reprint Association of transforming growth factor beta1 and tumor necrosis factor alpha polymorphisms with anti-SSB/La antibody secretion in patients with primary Sjögren's syndrome
    Jacques Eric Gottenberg
    Hopital de Bicetre, Assistance Publique Hopitaux de Paris, INSERM EMI 109, Le Kremlin Bicetre, France
    Arthritis Rheum 50:570-80. 2004
    ....
  73. doi request reprint Therapeutic potential for B-cell modulation in Sjögren's syndrome
    Xavier Mariette
    Hopital Bicetre, Assistance Publique Hopitaux de Paris AP HP, Universite Paris Sud 11, Le Kremlin Bicetre, Institut Pour la Santé et la Recherche Médicale INSERM U 802, France
    Rheum Dis Clin North Am 34:1025-33, x. 2008
    ..This B-cell activation is firstly polyclonal but can progress to monoclonal B-cell lymphoproliferation. This article addresses the therapeutic potential of B-cell modulation in Sjögren's syndrome...
  74. ncbi request reprint Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features
    Julien Champey
    Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Université Paris 11, Le Kremlin Bicetre, France
    Arthritis Rheum 55:451-7. 2006
    ....
  75. doi request reprint The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndrome
    Corinne Miceli-Richard
    INSERM U 802, Universite Paris Sud 11, Le Kremlin Bicetre, France
    Arthritis Rheum 60:1991-7. 2009
    ....
  76. ncbi request reprint Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy
    Benjamin Terrier
    Assistance Publique Hopitaux de Paris, Hopital de Bicetre, Le Kremlin Bicetre, France
    Arthritis Rheum 57:1520-9. 2007
    ..To evaluate the clinicobiologic presentation in patients with primary Sjögren's syndrome (SS)-related peripheral neuropathy, the histologic results of neuromuscular biopsy (NMB), and clinical outcome, and to identify prognostic factors...
  77. ncbi request reprint RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma
    Sophie Roux
    Service de Rhumatologie, Hopital de Bicetre, France
    Br J Haematol 117:86-92. 2002
    ..These results suggest that RANKL overexpressed by bone marrow stromal cells may contribute to the high rate of bone resorption observed in MM...